This was originally published on Global Health TV on July 16, 2016.
In comments last week at the International AIDS
Conference in Durban, South Africa, UN Secretary General Ban Ki-moon said four
things deserved credit for getting the AIDS pandemic under control — people
living with HIV, biomedical companies, generic medicines and international
finance.
But despite his gratitude to biomedical companies
and generic medicines, the secretary-general is overseeing a process that
threatens to undermine those companies' ability to improve access to medicine
in developing countries.
The World Health Organization says an estimated 2
billion people (27% of the world’s population of 7.5 billion) lack access to
essential medicine, most of them in Africa and Asia, but a full
three-quarters of the world’s population (around 5.5
billion) have no access to proper pain relief treatment.
To address
this staggering problem, the Secretary-General set up a High-Level Panel on Access to Medicines earlier this year. The purpose of
the panel was “to review and assess proposals and recommended solutions for
remedying the policy incoherence between the justifiable rights of inventors,
international human rights law, trade rules and public health in the context of
health technologies.”
Sounds like
a great and noble idea, right? But some expert commentators say the panel is on
track to do more harm than good because of its terms of reference.


